Picture Fairtec GmbH Worldwide Event Solutions 650x65px
Document › Details

PeptiDream Inc.. (4/2/15). "Press Release: PeptiDream Announces License of PeptiDream’s Peptide Discovery Platform System (PDPS) Technology to Novartis". Tokyo.

Organisations Organisation PeptiDream Inc. (JP)
  Organisation 2 Novartis AG (NYSE: NVS)
  Group Novartis (Group)
Products Product Peptide Discovery Platform System (PDPS) technology
  Product 2 peptide-based drug
Index term Index term Novartis–PeptiDream: drug discovery technology, 201504– license non-excl for use of PDPS technology by Novartis
Person Person Kubota, Kiichi (PeptiDream 201504 CEO)

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587) announced today that Swiss-based Novartis has exercised its option under their 2012 Strategic Alliance Agreement to obtain a nonexclusive license to PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the Technology License Agreement, PeptiDream will receive multi-stage upfront technology access payments, and will be eligible to receive development milestones and royalties on future sales of products that arise from use of the PDPS technology.

[Comments from Kiichi Kubota, CEO of PeptiDream Inc.]
“We are delighted with Novartis’s decision to internalize the PDPS technology under our 2012 Strategic Alliance Agreement, and this exercise further validates our PDPS technology as one of the best hit-finding/discovery platforms. The license agreement will significantly contribute to PeptiDream’s revenue both in the short term and has the potential to generate significant revenues long into the future.”

PeptiDream Inc
(Ticker Code:4587 TSE Mothers)

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide. For further information please visit


PeptiDream Inc.
Patrick C Reid +81-3-5790-9991 (Tokyo)

Record changed: 2019-06-09


Picture [LSUS] – The Business Web Portal 650x65px

More documents for PeptiDream Inc. (JP)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSA] – The Business Web Portal 650x89px

» top